Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flupirtine-based pain therapy

Drug Profile

Flupirtine-based pain therapy

Alternative Names: CNSB001; CNSB015

Latest Information Update: 19 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CNSBio
  • Developer Relevare Pharmaceuticals
  • Class Aminopyridines; Muscle relaxants; Non-opioid analgesics; Opiate alkaloids; Small molecules
  • Mechanism of Action KCNQ potassium channel agonists; NMDA receptor antagonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Neuropathic pain

Most Recent Events

  • 31 May 2010 Interim efficacy data from a phase IIa trial in HIV-related Neuropathic pain released by Relevare Pharmaceuticals
  • 28 May 2010 Relevare Pharmaceuticals completes a phase II trial in Neuropathic pain in Australia
  • 07 Oct 2008 Phase-I/II clinical trials in Neuropathic pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top